Muse bio is now Inscripta. Learn more
MADzymes
Unprecedented access to novel CRISPR nucleases
Inscripta is a gene editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity. This includes developing a family of CRISPR enzymes (called MADzymes), bespoke nucleases for researchers and commercial partners, and a full suite of gene editing tools (software, instruments, and reagents) that will significantly increase the speed and efficiency of precision gene editing.
Inscripta Raises $55.5 Million to Advance Gene-Editing Technology
Boulder, Colo. – February 28, 2018 – Inscripta, a leading gene-editing technology company, today announced that it has closed a $55.5 million Series C funding round led by Mérieux Développement and Paladin Capital Group.
Careers
